Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems for diabetes patients, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA.
The company will deliver a corporate overview and conduct one-on-one meetings during the conference on Tuesday, March 4, 2025, at 3:10 pm ET. Interested parties can access both live and recorded webcasts of the presentation through the 'Investor Relations' section of Senseonics' website at www.senseonics.com.
Details
News Market Reaction – SENS
The recorded move for SENS in the trading session of this news was -5.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GERMANTOWN, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming TD Cowen 45th Annual Health Care Conference, being held in Boston, MA.
TD Cowen 45th Annual Health Care Conference
Format: Corporate overview and one-on-one meetings
Date: Tuesday, March 4, 2025
Time: 3:10 pm ET
Webcast: Click here
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.